Findings

What do systematic reviews say?

461 questions · 472 findings · 42 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 93 · 19.7%GRADE not reported 81 · 17.2%Very low 99 · 21%Low 103 · 21.8%Moderate 75 · 15.9%High 21 · 4.4%

Ascorbic acid vs placebo

Change in 10‐metre walking time · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 406 participants
Moderate

Ascorbic acid vs placebo

Change in 9‐hole peg test (HPT) at 12 months (seconds) · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 224 participants
Moderate

Ascorbic acid vs placebo

Health‐related quality of life (physical) · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 400 participants
Moderate

Ascorbic acid vs placebo

Participation · people with fatigue in peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ascorbic acid vs placebo

Health‐related quality of life (mental) · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 123 participants
Moderate

Ascorbic acid vs placebo

Serious adverse events · people with fatigue in peripheral neuropathy

Ascorbic acid showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
RR 0.7 [0.39, 1.27]
2 studies · 450 participants
Moderate

Amantadine vs placebo

Fatigue · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amantadine vs placebo

Change in activity limitations · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amantadine vs placebo

Participation · people with fatigue in Guillain‐Barré syndrome

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
74 participants
Low

Amantadine vs placebo

Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amantadine vs placebo

Serious adverse events · people with fatigue in Guillain‐Barré syndrome

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
80 participants
GRADE not reported

Ascorbic acid vs placebo

Reduction in fatigue · people with fatigue in peripheral neuropathy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ascorbic acid vs placebo

Fatigue · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 404 participants
Moderate

Ascorbic acid vs placebo

Change in activity limitations · people with fatigue in peripheral neuropathy

1 finding from 1 review

Interventions for fatigue in peripheral neuropathy 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 406 participants
GRADE not reported

Hydroxytryptophan vs placebo

Short‐term (within 1 month) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Thyrotropin‐releasing hormone tartrate vs placebo

Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Thyrotropin‐releasing hormone tartrate vs placebo

Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Thyrotropin‐releasing hormone tartrate vs placebo

Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 320 participants
GRADE not reported

Thyrotropin‐releasing hormone tartrate vs placebo

Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Thyrotropin‐releasing hormone tartrate vs placebo

Economic outcomes · people with speech disorder resulting from hereditary ataxias

1 finding from 1 review

Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported